Tapan M. Kadia | MD Anderson Cancer Center

Dr. Tapan Kadia, MD

Claim this profile

M D Anderson Cancer Center

Expert in Acute Myeloid Leukemia
Studies Leukemia
24 reported clinical trials
37 drugs studied

About Tapan Kadia, MD

Education:

  • Obtained MD from Baylor College of Medicine, Houston, Texas, in 2005.
  • Completed Residency in Internal Medicine at The Johns Hopkins Hospital, Baltimore, Maryland (2005-2008).
  • Undertook Fellowship in Hematology/Oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas (2008-2011).

Experience:

  • Currently serves as a Professor of Medicine and Chief of the Section of Leukemia at The University of Texas MD Anderson Cancer Center.

Area of expertise

1

Acute Myeloid Leukemia

Global Leader

Tapan Kadia, MD has run 17 trials for Acute Myeloid Leukemia. Some of their research focus areas include:

HLA
prior malignancy
myelodysplastic syndrome
2

Leukemia

Tapan Kadia, MD has run 6 trials for Leukemia. Some of their research focus areas include:

HLA

Affiliated Hospitals

Image of trial facility.

M D Anderson Cancer Center

Image of trial facility.

The University Of Texas M.D. Anderson Cancer Center

Clinical Trials Tapan Kadia, MD is currently running

Image of trial facility.

Liposomal Daunorubicin-Cytarabine + Venetoclax

for Acute Myeloid Leukemia

This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine and venetoclax work in treating participants with acute myeloid leukemia that has come back (relapsed), does not respond to treatment (refractory), or has not been treated (untreated). Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Recruiting

1 award

Phase 2

Image of trial facility.

Decitabine + Other Drugs

for Acute Myeloid Leukemia

This phase Ib trial is to find out the side effects and possible benefits of decitabine alone or given together with venetoclax, gilteritinib, enasidenib, or ivosidenib in treating patients with acute myeloid leukemia that is under control (remission). Chemotherapy drugs, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of cancer cells by blocking a protein called Bcl-2 needed for cell growth. Gilteritinib, enasidenib, and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving decitabine alone or together with venetoclax, gilteritinib, enasidenib, or ivosidenib may help to control the disease.

Recruiting

1 award

Phase 1

14 criteria

More about Tapan Kadia, MD

Clinical Trial Related

6 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 9 Active Clinical Trials

Treatments Tapan Kadia, MD has experience with

  • Venetoclax
  • Decitabine
  • Cladribine
  • Cytarabine
  • APG-2575
  • Azacitidine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Tapan Kadia, MD specialize in?

Is Tapan Kadia, MD currently recruiting for clinical trials?

Are there any treatments that Tapan Kadia, MD has studied deeply?

What is the best way to schedule an appointment with Tapan Kadia, MD?

What is the office address of Tapan Kadia, MD?

Is there any support for travel costs?